Project Grant R13AR085978
Award Date
7/7/25
Completion Date
6/30/26
Dollars Obligated
$60K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $385,575 to the University of California, San Diego (UCSD) to conduct research on the genetic and immunological mechanisms underlying a severe childhood autoimmune disorder known as disabling pansclerotic morphea (DPM). The key objectives of this 5-year project are to: 1) determine how a gain-of-function mutation in...
This Cooperative Agreement from the National Institutes of Health (NIH) under the 21st Century Cures Act: Regenerative Medicine Initiative (CFDA 93.370) provides $538,200.00 to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, to conduct a Phase 1 pilot study on the safety and efficacy of induced pluripotent stem cell (iPSC)-based therapy for recessive dystrophic epidermolysis bullosa (RDEB). The study will evaluate the use of genetically...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Panorama Research Incorporated, doing business as Panorama Research Inc., a $275,765 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop an antibody-based therapy for reducing scarring and fibrosis following joint surgeries. The project aims to improve the delivery and tissue residence of a lead humanized antibody that inhibits collagen fibril formation, thereby...
This Project Grant award of $147,400.00, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the mechanisms by which antigen non-related CD4+ T cells contribute to the pathogenesis of skin fibrosis in systemic sclerosis (scleroderma) and sclerodermoid graft-versus-host disease. The project, conducted by Yale University, will use mouse models to...
This federal Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA Program 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research, is funding a research project to assess the use of Spatial Frequency Domain Imaging (SFDI) as an objective measure for tracking skin changes in systemic sclerosis (scleroderma) patients over time. The $173,719 award to Trustees of Boston University's Medical Campus will be used to...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports the development of a novel peptide-based therapeutic agent called M10 for the treatment of skin fibrosis associated with systemic sclerosis (scleroderma). The $613,036 award to Fibrobiologics LLC aims to determine the antifibrotic activity of M10 in primary skin fibroblasts from scleroderma...
This Cooperative Agreement award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $536,233 to Northwestern University to develop a synthetic melanin-based treatment to accelerate wound healing and reduce scarring resulting from exposure to mustard gas. The project aims to evaluate a group of synthetic melanin particles (SMPs) for their ability to mitigate initial skin injury and promote faster wound repair...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is focused on defining and treating genetic abnormalities in psoriasis/atopic dermatitis-overlap dermatoses. The total award amount is $628,968.00 with a project period from June 20, 2025 to April 30, 2030. The awardee is The Regents of the University of California, San Francisco (UCSF), a prominent...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $384,250 to the University of Alabama at Birmingham (UAB) to elucidate the nature of immune-stem cell interactions inadvertently targeted by immunotherapies. The project will investigate signaling between the immune checkpoint proteins PD-1 and PD-L1 as a mechanism by which immune cells and melanocyte stem cells...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $100,000.00 to the University of Pittsburgh to study the role of cytokines and inflammatory pathways in systemic sclerosis-associated interstitial lung disease (SSc-ILD). The research aims to refine explant culture methodologies and examine the effects of key cytokines, such as TGF-β, PDGF, IL-6, and IL-13, on lung cell gene expression in healthy control and...